Medindia

X

Diabetes Complications Pipeline Has High Potential for Change as 30% of Products Considered First-in-Class, says GBI Research

Tuesday, June 28, 2016 Research News J E 4
Advertisement

LONDON, June 28, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Frontier Pharma: Diabetic Complications - states that the diabetes complications space has high potential for changes and improvements as it becomes more diverse, with 30% of diabetic complication products in active development considered to be first-in-class.

The market for diabetic complications is predominantly composed of therapies that symptomatically treat the condition and, at best, slow disease progression. However, as the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options, particularly in order to develop therapies that are more aligned with the underlying disease pathophysiology.

Associate Analyst Firas Nour states that: "Although many first-in-class products fail to make an impact on the market even upon successful regulatory approval, higher-risk programs for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products of the past decade, including Avastin (bevacizumab) for diabetic macular edema and Rituxan (rituximab) for diabetic neuropathy."

GBI Research has found that 31.7% of products in the entire metabolic pipeline were first-in-class, which means that diabetic neuropathies have a below-average proportion of first-in-class pipeline products. In the diabetic retinopathies segment, however, there is substantial innovation in the early pipeline, which offers signs that a greater proportion of first-in-class products will filter through to Phase III in the future."

Deal activity within the diabetic complications market varies with first-in-class status. Strategic consolidations have played an important role in developing therapeutics for diabetic complications in the past decade, with 81 licensing deals and 36 co-development deals having taken place since 2006.

Nour continues: "The deals in diabetic complications revealed that licensing deals did not reflect the industry-wide trend of first-in-class deals being more valuable. Co-development deals, meanwhile, were representative of the overall picture of the complications pipeline, reflecting the shift towards therapies that are more aligned with the underlying disease pathophysiology."

Sample pages of GBI Research's report Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44 161 359 5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter

SOURCE GBI Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Montefiore and Burke to Establish Center of Excell...
S
Psoriasis Drugs Market Forecasts 2016-2026